Categories
Global stocks

Boston Beer Faces Shipment Declines as Hard Seltzer Continues to Struggle

Business Strategy & Outlook:
Though much smaller than the brewing behemoths, Boston Beer is well positioned in malt categories, boasting a meaningful growth profile that mainstream beer lacks. The firm has shown a remarkable proclivity to not only augment its portfolio in alignment with the latest growth vectors but to also capture a disproportionate share of the economic rents generated from this growth by being one of the first movers. One can see this exemplified in the company’s participation in the initial rises of craft beer, cider, and more recently, hard seltzer. While seltzer trends have slowed significantly, its surmise sales at Boston Beer will continue to be supported by secular consumption shifts (such as the desire for a low-sugar footprint and varied flavor profiles, and as evidenced by the success of Truly Margarita and the launch of Truly Vodka Seltzer).

To admit Boston Beer’s growth trajectory is not without risk. Due to the torrid growth that hard seltzer had achieved in prior years, a slew of new entrants led to dizzying saturation that has had a discernible impact on category growth (an issue creeping into other RTD areas). Additionally, U.S. craft beer remains oversaturated as per view, with peers spanning from local upstarts to large multinationals. Microbreweries have been taking share from established players like Boston Beer, as parochial preferences seem to be driving many consumers toward locally produced beers with small and homely essences. Nevertheless, the firm has meaningful scale advantages over the thousands of small craft breweries operating in the U.S., driving superior unit economics and stellar profitability that allows it to pivot its portfolio and go-to-market approach as necessary. The 2019 Dogfish Head acquisition is an example of this, as the firm had the resources to add a fast-growing, locally resonant family of brands to its mix. Its stalwart positioning also funds fruitful innovation, from incremental initiatives such as its custom beer can, to blockbuster breakthroughs like Truly. Ultimately, to see Boston Beer as a well-run and high-quality operator and believe it has the tools to succeed in a landscape that is in flux.

Financial Strengths:
To assign Boston Beer an Exemplary capital allocation rating, as the firm stacks up admirably against two of the three pillars of framework: Its balance sheet is pristine, and its organic investments have unequivocally been value-accretive in view. While to take a mixed view of its distribution philosophy, to expect investments to be the pre-eminent driver of future shareholder returns, and the company’s suboptimal corporate governance, while worth highlighting, has not had a demonstrably adverse impact on capital allocation up to this point. Regarding investments, as per view on the management team is constructive, and to see as particularly impressive the brewer’s innovation track record across multiple categories and consequent ability to align its portfolio with this century’s malt growth vectors. Boston Beer’s current CEO, Dave Burwick, joined the firm in 2018 following an equivalent role at Peet’s Coffee & Tea as well as senior executive positions at Weight Watchers International and PepsiCo. Burwick’s tenure was preceded by Martin Roper, who announced plans to retire in 2018 after 17 years at the helm. Towering over these operational leaders has been Jim Koch, who founded Boston Beer in 1984, chairs its board, and remains integrally involved in the company’s strategic direction. To believe Koch, his CEOs, and their respective teams, have done a commendable job providing rudder for a firm competing within a dynamic brewing landscape. This is evidenced by the brewer’s consistent positioning as an innovation bellwether within the U.S. malt space, having been at the forefront of high-growth categories like craft beer, cider, and hard seltzer. Innovative efforts into categories like hard seltzer should provide economic value ahead, as the favorable secular dynamics (chiefly health consciousness and premiumization) underpinning the category’s robust adoption (over half a decade of triple-digit growth) should persist at a more normalized level ahead. Despite being number two in the space (behind White Claw), management has fended off a deluge of competition from giants like AB InBev and Constellation Brands, maintaining or growing share. Being at the vanguard of innovation has been core to this success, and this favorable category should continue to offset challenging dynamics in craft and hard cider. The firm was all but inactive on the M&A front prior to 2019, when it consummated its largest acquisition to date of Dogfish Head, a Delaware-based craft brewery, for roughly $330 million in cash and stock.

As per the strategic rationale for the deal is prudent, as the smaller scale and local essence of Dogfish Head’s brands (which resonate more deeply with many craft drinkers) augment the growth profile of Boston Beer’s craft portfolio. However, the over 3 times forward sales multiple that was paid was a bit rich, as evidenced in the $27.1 million impairment of intangible assets the firm took in 2022 as forecasts for brand performance were below those made on the acquisition date. While ostensibly stepping back from the operational helm in 2001, one believes Jim Koch continues to wield unencumbered authority over decision-making at the company. This is so because, within the dual share class structure that the firm operates, Koch owns substantially all the class A stock, giving him the preponderance of voting rights as well as the power to elect the majority of board directors. Koch’s carte blanche is evinced not only by his voting rights but also his wife’s position as a long-standing member of the board. From the vantage point, these realities not only give rise to material key-person risk, but also a heightened probability of misaligned incentives between Jim Koch and class B common stock owners. Still, until this reality manifests in clearly injudicious capital allocation, we’ll place qualms here on the back burner. Regarding distributions, Boston Beer has never paid a dividend, instead deploying its free cash flow toward share repurchases. To take a dim view of the firm’s indiscriminate approach to share repurchases, but this view is countervailed by the fact that internal reinvestment takes precedence over cash returns in management’s capital allocation priorities. Additionally, given the company’s long-term commitment to share buybacks, to believe there have been times when buybacks have been executed at prices above intrinsic value, as well as prices below, ultimately netting to a value-neutral impact. One does not expect the company to pay a dividend throughout the explicit forecast, but continue to model meaningful repurchases, which should average around $170 million on average over the next five years.

Bulls Say:
Boston Beer competes exclusively at the high end of malt beverages, which are seen as secularly advantaged relative to mainstream and value segments.
The firm is one of two market incumbents in hard seltzer, which offers it an easier route to grow the top line through innovative product offerings.
Thanks to historical successes across the FMB and RTD products, Boston Beer has a unique ability to elevate category innovation through a well-established distribution network.

Company Description:
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.

(Source: Morningstar)
DISCLAIMER for General Advice: (This document is for general advice only).
This document is provided by Laverne Securities Pty Ltd T/as Investor Desk. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Investor Desk and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Investor Desk and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Investor Desk and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Investor Desk and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Investor Desk and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Investor Desk and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Investor Desk and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Investor Desk and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Investor Desk and Banyan Tree.

Categories
Technology Stocks

CRISPR Therapeutics’ Pipeline Continues to Make Progress; FVE Remains $119; Shares Very Undervalued

Business Strategy & Outlook: 

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company’s proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations. CRISPR/Cas9 works by having CRISPR (pieces of DNA sequences) guide Cas9 (an enzyme that can cut and edit DNA) to edit, alter, or repair genes. The company’s proprietary technology has the potential to build blockbusters in rare diseases with limited treatment options available. CRISPR Therapeutics currently has no approved drugs and a largely early-stage pipeline, so to refrain from awarding the company an economic moat. CRISPR Therapeutics is focused on developing and commercializing novel therapies to treat severe, genetic diseases and currently possesses a sizeable, yet mostly early-stage pipeline. Its lead candidate, CTX001, is being developed in collaboration with narrow-moat Vertex Pharmaceuticals for the treatment of transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD). CRISPR Therapeutics and Vertex plan to file for regulatory approval by the end of 2022. The rest of CRISPR Therapeutics’ pipeline is either in early (Phase 1) or pre-clinical stages of development. While CRISPR Therapeutics does not currently have approved products, the company provides long-term investors with pure play exposure to gene editing.

Financial Strengths: 

To assign CRISPR Therapeutics a Standard capital allocation rating. Analysis evaluates what to determine to be the three key facets of management decision-making from the perspective of shareholders: balance sheet strength, investment efficacy, and distributions. The Standard rating results from a sound balance sheet, fair investment strategy, and an assessment of shareholder distributions as appropriate. CRISPR Therapeutics’ revenue cyclicality possesses a medium rating and its operating leverage has a low rating. To assess the company’s balance sheet as sound due to management’s demonstrated ability to maintain little to no debt and run a fairly lean operation despite heavily investing in R&D as it works to advance its pipeline candidates. As of year-end 2021, CRISPR Therapeutics had nearly $2.4 billion in cash and investments.

CRISPR Therapeutics’ investment decisions were fair. As an early-stage biotechnology company, it invests heavily in R&D since it’s focusing on developing its pipeline. CRISPR Therapeutics is investing in its gene editing technology to treat a diverse range of severe, genetic diseases. The validation of the company’s gene editing technology through FDA approvals will be crucial as it competes with other companies also entering the gene editing space. If approved, CRISPR Therapeutics’ drugs could be quite lucrative due to high unmet medical needs leading to pricing power. Finally, to assess overall shareholder distributions as appropriate. Even though the company does not currently pay a dividend, to view this as appropriate since CRISPR Therapeutics is investing in its pipeline to help build value for shareholders. CRISPR Therapeutics is led by Dr. Samarth Kulkarni, who joined the company in 2015 initially as Chief Business Officer. Prior to joining CRISPR Therapeutics, Kulkarni was a partner at McKinsey & Company in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy.

Bulls Say:

  • Partnerships allow CRISPR Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs. 
  • CRISPR Therapeutics’ CRISPR/Cas9 platform has the potential to develop highly efficacious and potentially curative treatments for rare, genetic diseases with high unmet needs, which will likely lead to pricing power.
  • To view the company’s pipeline as possessing strengthening intangible assets and assign it a positive moat trend.

Company Description:

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Investor Desk. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Investor Desk and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Investor Desk and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Investor Desk and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Investor Desk and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Investor Desk and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Investor Desk and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Investor Desk and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Investor Desk and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Investor Desk and Banyan Tree.